<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954082</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0053</org_study_id>
    <secondary_id>U10HD021364</secondary_id>
    <secondary_id>U10HD040689</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>U10HD027851</secondary_id>
    <secondary_id>U10HD027853</secondary_id>
    <secondary_id>U10HD027856</secondary_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD034216</secondary_id>
    <secondary_id>U10HD021373</secondary_id>
    <secondary_id>U10HD040492</secondary_id>
    <secondary_id>U10HD053109</secondary_id>
    <secondary_id>U10HD053089</secondary_id>
    <secondary_id>U10HD068244</secondary_id>
    <secondary_id>U10HD068263</secondary_id>
    <secondary_id>U10HD068270</secondary_id>
    <secondary_id>U10HD068278</secondary_id>
    <secondary_id>U10HD068284</secondary_id>
    <secondary_id>U10HD036790</secondary_id>
    <nct_id>NCT01954082</nct_id>
  </id_info>
  <brief_title>Inositol to Reduce Retinopathy of Prematurity</brief_title>
  <acronym>INS-3</acronym>
  <official_title>INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, double-masked, placebo-controlled study designed to determine
      the effectiveness of myo-Inositol 5% Injection to increase the incidence of survival without
      severe Retinopathy of Prematurity (ROP) through acute/final ROP determination up to 55 weeks
      postmenstrual age (PMA) in premature infants &lt;28 0/7 weeks' gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 1760 infants are to be enrolled at approximately 18 Eunice Kennedy Shriver
      National Institute of Child Health and Human Development (NICHD) Neonatal Research Network
      (NRN) Centers (approximately 44 sites) in the United States. Infants meeting the study
      selection criteria and for whom informed consent is obtained will be randomized to receive
      either 80 mg inositol/kg/day or placebo, administered in divided doses every 12 hours (40
      mg/kg/dose). Study drug will be administered daily, starting within 12 to 72 hours of birth
      and continued until the earliest of 34 weeks PMA, 10 weeks chronologic age, or the time of
      hospital discharge or transfer. Inositol or placebo will be administered IV until enteral
      feedings reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at
      which time the same dose and formulation will be administered enterally every 12 hours.

      For publication purposes, the analysis of the primary efficacy outcome will consider the
      entire study population. In support of a new drug application (NDA) for use of myo-Inositol
      5% Injection to increase survival without severe ROP through the determination of acute/final
      ROP status, the analysis of the primary efficacy outcome will be conducted for the entire
      study population and separately within pre-specified regulatory sub-studies created by
      administratively splitting infants enrolled at each study center into two sub-studies.

      Assessments performed during the study include customary newborn intensive care procedures
      including repeat eye examinations until ROP status is final (which often extends after
      discharge), measurements of growth, cranial ultrasounds or other imaging per usual practice,
      and the collection of clinical diagnoses throughout hospitalization to evaluate other common
      morbidities of extreme preterm birth. Adverse events will be recorded from time of treatment
      initiation until 7 days after the last dose of study drug, and concurrent medications will be
      recorded from 24 hours prior to randomization until 7 days after the last dose of study drug
      or until discharge or transfer if sooner. Using the separate NICHD Follow-up protocol, longer
      term data will be collected at 22-26 months corrected age, including growth,
      neurodevelopmental testing, overall health status, rehospitalizations, surgeries and
      diagnoses, including ophthalmic diagnoses and treatments since discharge.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to safety concerns; participant follow up will continue until March 2018
  </why_stopped>
  <start_date>April 17, 2014</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Unfavorable Outcome, Defined as Severe Retinopathy of Prematurity (ROP) or Death Prior to Reaching Acute/Final ROP Status</measure>
    <time_frame>by 55 weeks PMA</time_frame>
    <description>Death is defined as from any cause before Acute/Final ROP status is determined. ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. The favorable ROP endpoint requires that no ROP, or only mild ROP has occurred in both eyes and the eyes have matured beyond the risk of developing Type 1 ROP (severity meeting criteria for surgical intervention). The unfavorable ROP endpoint requires that one or both eyes reach Type 1 ROP. When ROP did not resolve by the time of discharge, participants were followed as outpatients until reaching an ROP endpoint, up to 55 weeks PMA. Since incomplete follow up is more likely among participants with mild or no ROP than for those with aggressive ROP, an independent adjudication process assigned an ROP endpoint of 'most likely never had Type 1 ROP', or 'most likely developed Type 1 ROP' based on clinical and ROP data review to reduce possible missing data bias.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bronchopulmonary Dysplasia (BPD)</measure>
    <time_frame>36 weeks PMA</time_frame>
    <description>BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of &gt;90% at 36 weeks postmenstrual age (PMA) (NICHD physiologic definition).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bronchopulmonary Dysplasia (BPD) or Death From BPD</measure>
    <time_frame>prior to 37 weeks PMA</time_frame>
    <description>BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of &gt;90% at 36 weeks PMA (NICHD physiologic definition). Death from BPD prior to 37 weeks postmenstrual age (PMA) is defined when the cause of death is certified by the Center PI as BPD being the primary cause, or a significant co-contributing cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Cause Death Before Retinopathy of Prematurity (ROP) Endpoint</measure>
    <time_frame>by 55 weeks PMA age</time_frame>
    <description>Defined as death from any cause following randomization through primary study follow-up (up to 55 weeks postmenstrual age (PMA))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Retinopathy of Prematurity (ROP)</measure>
    <time_frame>by 55 weeks PMA</time_frame>
    <description>ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. Any ROP is defined as ROP of any severity that is observed on at least 2 independent examinations in either eye through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Type 2 or More Severe Retinopathy of Prematurity (ROP)</measure>
    <time_frame>by 55 weeks PMA</time_frame>
    <description>Defined as one or both eyes reaching Type 2 ROP (ETROP 2003) or the more severe Type 1 ROP (as defined previously) through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)). Type 2 ROP is defined as (ETROP 2003): Stage 3 ROP without Plus Disease (i.e. Zone II) or Stage 1 or 2 ROP without Plus Disease (i.e. Zone I).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Intraventricular Hemorrhage (IVH)</measure>
    <time_frame>by 28 days PMA</time_frame>
    <description>Severe IVH is defined as IVH Grades 3 or 4 on either side of the brain. The evaluation for IVH occurs early (within 28 days from birth) via a cranial sonogram and is classified as described by Papile.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Occurrence of Adverse Events and Serious Adverse Events</measure>
    <time_frame>7 days post study drug discontinuation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Necrotizing Enterocolitis (NEC)</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <description>Stage II or worse, whether treated (medically or surgically) and if the infant survived (modified Bell's classification [Walsh 1986]).</description>
  </other_outcome>
  <other_outcome>
    <measure>Isolated Gastrointestinal Perforation</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <description>judged not to be due to NEC</description>
  </other_outcome>
  <other_outcome>
    <measure>Late Onset Sepsis</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <description>culture positive septicemia/bacteremia (≥72 hours of age) treated with antibiotics for ≥ 5 days or died before treatment was completed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patent Ductus Arteriosus (PDA)</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <description>Occurrence of clinically significant patent ductus arteriosus (PDA), and if received intervention with prostaglandin inhibitors, and/or surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Seizures</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <description>Seizures treated with an anticonvulsant for &gt;72 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Days on Parenteral Nutrition</measure>
    <time_frame>NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <description>Total days on parenteral nutrition (including amino acids and/or lipids)</description>
  </other_outcome>
  <other_outcome>
    <measure>Days on Oxygen, Days on Ventilator</measure>
    <time_frame>NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hearing Loss</measure>
    <time_frame>NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <description>Hearing loss as defined as never passing a hearing screening in one or both ears</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurodevelopment</measure>
    <time_frame>22-26 months corrected age</time_frame>
    <description>Neurodevelopment at 22-26 months corrected age (i.e., 22-26 months past due date) using the Bayley Scales of Infant Development III.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vision Loss</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <description>Vision loss as diagnosed by an ophthalmologist as legally blind, and subdivided into &quot;ophthalmic origin&quot;, or &quot;not ophthalmic origin&quot; (i.e., cortical blindness is non-ophthalmic in origin and indicates that there is no retinal detachment or other abnormal fundus or ocular finding, except optic atrophy. Such cases will be considered central [neurologic] in origin.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Hearing Loss</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <description>Hearing loss requiring that hearing aids be prescribed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cerebral Palsy</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <description>Cerebral palsy by severity category (absent/mild/moderate/severe).</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Health Status</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <description>Overall health status per recall from the parent/guardian (including survival, re-hospitalizations, surgeries, ongoing medications, and chronic illnesses).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">638</enrollment>
  <condition>Retinopathy of Prematurity (ROP)</condition>
  <arm_group>
    <arm_group_label>myo-Inositol 5% Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% glucose(dextrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>myo-Inositol 5% Injection</intervention_name>
    <description>Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.
Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose).</description>
    <arm_group_label>myo-Inositol 5% Injection</arm_group_label>
    <other_name>Inositol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>% glucose(dextrose)</description>
    <arm_group_label>5% glucose(dextrose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inborn or out born infants of either gender or any race with best obstetrical estimate
             of gestation &lt;28 weeks (27 6/7 weeks and younger). Gestational age will be determined
             by best obstetrical estimate using the hierarchy of best obstetrical estimate using
             early ultrasound dating, maternal menstrual dating confirmed by examination, or
             neonatal gestational age assessment by physical examination.

          -  Alive at 12 hours.

          -  Age in hours up to 72 hours, although we will seek enrollment as early as feasible
             after consent and 12 hours.

          -  Informed consent signed and dated by parent and/or guardian, which includes likelihood
             of completing follow-up ophthalmic examinations as an outpatient, and long-term
             follow-up.

        Exclusion Criteria

          -  Major congenital malformations

          -  Congenital malformations of the eye identified prior to randomization.

          -  Overt evidence of intrauterine congenital infections (&quot;TORCH&quot;) or life threatening
             impairment of renal, hepatic, or cardiac function (considered moribund).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele C Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University, Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhik Das, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seetha Shankaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Schibler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greg Sokol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abbot R Laptook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Women &amp; Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krisa P Van Meurs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemar A Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen A Kennedy, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald N Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward F Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dale L Phelps, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl T D'Angio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Truog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute at Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uday Devaskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myra Wyckoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Southwestern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristi L Watterberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neonatal.rti.org/</url>
    <description>NICHD NRN Website</description>
  </link>
  <link>
    <url>https://www.nichd.nih.gov/about/org/der/branches/ppb/Pages/projects.aspx</url>
    <description>NICHD Pregnancy &amp; Perinatology Branch</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <results_first_submitted>December 29, 2017</results_first_submitted>
  <results_first_submitted_qc>August 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 26, 2018</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinopathy</keyword>
  <keyword>Prematurity</keyword>
  <keyword>Infant, Newborn, Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>One year after primary publication</ipd_time_frame>
    <ipd_access_criteria>NICHD Data and Specimen Repository (DASH)</ipd_access_criteria>
    <ipd_url>https://dash.nichd.nih.gov/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From April 2014 to September 2015, infants born before 28 weeks gestation and surviving &gt;12 hours were screened when admitted to one of the 18 NICHD NRN Centers (approximately 44 sites) in the United States and enrolled in the study if they met the eligibility criteria and consent was obtained before 72 hours postnatal age.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Myo-Inositol 5% Injection</title>
          <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
        </group>
        <group group_id="P2">
          <title>5% Glucose(Dextrose)</title>
          <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
                <participants group_id="P2" count="321"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="313">The 4 participants who were not treated either died (3) or withdrew before treatment start (1).</participants>
                <participants group_id="P2" count="319">The 2 participants who were not treated died before treatment start.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="249">There were 22 infants that received more doses than intended per protocol.</participants>
                <participants group_id="P2" count="264">There were 27 infants that received more doses than intended per protocol.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Suspension</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intolerance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued Early Prior to Transfer</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Redirection of Care</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscalculation of Final Dose Day</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Comfort Care</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Infant Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not Treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Myo-Inositol 5% Injection</title>
          <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
        </group>
        <group group_id="B2">
          <title>5% Glucose(Dextrose)</title>
          <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="317"/>
            <count group_id="B2" value="321"/>
            <count group_id="B3" value="638"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.64" spread="1.42"/>
                    <measurement group_id="B2" value="25.72" spread="1.34"/>
                    <measurement group_id="B3" value="25.68" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" lower_limit="22.0" upper_limit="27.9"/>
                    <measurement group_id="B2" value="25.9" lower_limit="22.7" upper_limit="27.9"/>
                    <measurement group_id="B3" value="25.9" lower_limit="22.0" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gestational Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;26 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=26 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <population>Age at start of study therapy is only available for infants who started treatment (313 Inositol and 319 Placebo).</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AGE AT START OF STUDY THERAPY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="313"/>
                    <count group_id="B2" value="319"/>
                    <count group_id="B3" value="632"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="0.8"/>
                    <measurement group_id="B2" value="2.8" spread="0.8"/>
                    <measurement group_id="B3" value="2.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <population>Age at start of study therapy is only available for infants who started treatment (313 Inositol and 319 Placebo).</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>AGE AT START OF STUDY THERAPY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="313"/>
                    <count group_id="B2" value="319"/>
                    <count group_id="B3" value="632"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B2" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="B3" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="317"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="317"/>
                    <measurement group_id="B2" value="321"/>
                    <measurement group_id="B3" value="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BIRTH WEIGHT</title>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="776.1" spread="195"/>
                    <measurement group_id="B2" value="784.6" spread="198.2"/>
                    <measurement group_id="B3" value="780.4" spread="196.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BIRTH WEIGHT</title>
          <units>Grams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="740" lower_limit="394" upper_limit="1390"/>
                    <measurement group_id="B2" value="765" lower_limit="300" upper_limit="1589"/>
                    <measurement group_id="B3" value="750" lower_limit="300" upper_limit="1589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ANTENATAL STEROIDS</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="564"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EARLY ONSET SEPSIS</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="622"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APGAR-5 MINUTE</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Test Result Available</title>
                  <measurement_list>
                    <measurement group_id="B1" value="313"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="629"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Test Result Not Available</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APGAR-5 MINUTE</title>
          <description>10-point, ordinal scale specifying infant's overall health 5 minutes after birth from 1 (needs immediate medical help) to 10 (in optimal health).</description>
          <units>Units on a Scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="317"/>
                    <count group_id="B2" value="321"/>
                    <count group_id="B3" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B2" value="6" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B3" value="6" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unfavorable Outcome, Defined as Severe Retinopathy of Prematurity (ROP) or Death Prior to Reaching Acute/Final ROP Status</title>
        <description>Death is defined as from any cause before Acute/Final ROP status is determined. ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. The favorable ROP endpoint requires that no ROP, or only mild ROP has occurred in both eyes and the eyes have matured beyond the risk of developing Type 1 ROP (severity meeting criteria for surgical intervention). The unfavorable ROP endpoint requires that one or both eyes reach Type 1 ROP. When ROP did not resolve by the time of discharge, participants were followed as outpatients until reaching an ROP endpoint, up to 55 weeks PMA. Since incomplete follow up is more likely among participants with mild or no ROP than for those with aggressive ROP, an independent adjudication process assigned an ROP endpoint of 'most likely never had Type 1 ROP', or 'most likely developed Type 1 ROP' based on clinical and ROP data review to reduce possible missing data bias.</description>
        <time_frame>by 55 weeks PMA</time_frame>
        <population>The analysis was performed on an intention to treat basis, including adjudicated ROP endpoints. Individuals for whom adjudicated ROP endpoints could not be obtained were treated as missing completely at random, and excluded from the primary analyses (4 Inositol and 1 Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Myo-Inositol 5% Injection</title>
            <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
          </group>
          <group group_id="O2">
            <title>5% Glucose(Dextrose)</title>
            <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unfavorable Outcome, Defined as Severe Retinopathy of Prematurity (ROP) or Death Prior to Reaching Acute/Final ROP Status</title>
          <description>Death is defined as from any cause before Acute/Final ROP status is determined. ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. The favorable ROP endpoint requires that no ROP, or only mild ROP has occurred in both eyes and the eyes have matured beyond the risk of developing Type 1 ROP (severity meeting criteria for surgical intervention). The unfavorable ROP endpoint requires that one or both eyes reach Type 1 ROP. When ROP did not resolve by the time of discharge, participants were followed as outpatients until reaching an ROP endpoint, up to 55 weeks PMA. Since incomplete follow up is more likely among participants with mild or no ROP than for those with aggressive ROP, an independent adjudication process assigned an ROP endpoint of 'most likely never had Type 1 ROP', or 'most likely developed Type 1 ROP' based on clinical and ROP data review to reduce possible missing data bias.</description>
          <population>The analysis was performed on an intention to treat basis, including adjudicated ROP endpoints. Individuals for whom adjudicated ROP endpoints could not be obtained were treated as missing completely at random, and excluded from the primary analyses (4 Inositol and 1 Placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on the development of severe ROP and mortality.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0095</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Robust Poisson</method>
            <method_desc>Model adjusted for strata defined by center and gestational age.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
            <estimate_desc>In the risk ratio, the numerator represents the Inositol arm and the denominator represents the placebo arm. (RR&gt;1 implies that the risk of mortality and/or severe ROP is greater in the Inositol group compared to the Placebo group).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bronchopulmonary Dysplasia (BPD)</title>
        <description>BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of &gt;90% at 36 weeks postmenstrual age (PMA) (NICHD physiologic definition).</description>
        <time_frame>36 weeks PMA</time_frame>
        <population>The analysis was performed on an intention to treat basis. Individuals for whom BPD outcome could not be obtained were treated as missing completely at random, and excluded from the analyses (45 Inositol and 33 Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Myo-Inositol 5% Injection</title>
            <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
          </group>
          <group group_id="O2">
            <title>5% Glucose(Dextrose)</title>
            <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bronchopulmonary Dysplasia (BPD)</title>
          <description>BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of &gt;90% at 36 weeks postmenstrual age (PMA) (NICHD physiologic definition).</description>
          <population>The analysis was performed on an intention to treat basis. Individuals for whom BPD outcome could not be obtained were treated as missing completely at random, and excluded from the analyses (45 Inositol and 33 Placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on the incidence of BPD.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6599</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Robust Poisson regression</method>
            <method_desc>Model adjusted for strata defined by center and gestational age.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>In the risk ratio, the numerator represents the Inositol arm and the denominator represents the placebo arm. (RR&gt;1 implies that the risk of BPD is greater in the Inositol group compared to the Placebo group).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bronchopulmonary Dysplasia (BPD) or Death From BPD</title>
        <description>BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of &gt;90% at 36 weeks PMA (NICHD physiologic definition). Death from BPD prior to 37 weeks postmenstrual age (PMA) is defined when the cause of death is certified by the Center PI as BPD being the primary cause, or a significant co-contributing cause of death.</description>
        <time_frame>prior to 37 weeks PMA</time_frame>
        <population>The analysis was performed on an intention to treat basis. Individuals who died prior to 37 weeks PMA for whom the cause(s) of death are unknown or individuals for whom BPD outcome could not be obtained were treated as missing completely at random, and excluded from the analyses (1 Inositol and 5 Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Myo-Inositol 5% Injection</title>
            <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
          </group>
          <group group_id="O2">
            <title>5% Glucose(Dextrose)</title>
            <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bronchopulmonary Dysplasia (BPD) or Death From BPD</title>
          <description>BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of &gt;90% at 36 weeks PMA (NICHD physiologic definition). Death from BPD prior to 37 weeks postmenstrual age (PMA) is defined when the cause of death is certified by the Center PI as BPD being the primary cause, or a significant co-contributing cause of death.</description>
          <population>The analysis was performed on an intention to treat basis. Individuals who died prior to 37 weeks PMA for whom the cause(s) of death are unknown or individuals for whom BPD outcome could not be obtained were treated as missing completely at random, and excluded from the analyses (1 Inositol and 5 Placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on the incidence of BPD or on mortality due to BDP.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3883</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Robust Poisson regression</method>
            <method_desc>Model adjusted for strata defined by center and gestational age.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Cause Death Before Retinopathy of Prematurity (ROP) Endpoint</title>
        <description>Defined as death from any cause following randomization through primary study follow-up (up to 55 weeks postmenstrual age (PMA))</description>
        <time_frame>by 55 weeks PMA age</time_frame>
        <population>The analysis was performed on an intention to treat basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Myo-Inositol 5% Injection</title>
            <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
          </group>
          <group group_id="O2">
            <title>5% Glucose(Dextrose)</title>
            <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Cause Death Before Retinopathy of Prematurity (ROP) Endpoint</title>
          <description>Defined as death from any cause following randomization through primary study follow-up (up to 55 weeks postmenstrual age (PMA))</description>
          <population>The analysis was performed on an intention to treat basis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on survival to ROP endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0306</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Robust Poisson regression</method>
            <method_desc>Model adjusted for strata defined by center and gestational age.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
            <estimate_desc>In the risk ratio, the numerator represents the Inositol arm and the denominator represents the placebo arm. (RR&gt;1 implies that the risk of mortality prior to ROP endpoint is greater in the Inositol group compared to the Placebo group).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Retinopathy of Prematurity (ROP)</title>
        <description>ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. Any ROP is defined as ROP of any severity that is observed on at least 2 independent examinations in either eye through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)).</description>
        <time_frame>by 55 weeks PMA</time_frame>
        <population>The analysis was performed on an intention to treat basis. Individuals for whom ROP status could not be defined were treated as missing completely at random, and excluded from the analyses (50 Inositol and 35 Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Myo-Inositol 5% Injection</title>
            <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
          </group>
          <group group_id="O2">
            <title>5% Glucose(Dextrose)</title>
            <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Retinopathy of Prematurity (ROP)</title>
          <description>ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. Any ROP is defined as ROP of any severity that is observed on at least 2 independent examinations in either eye through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)).</description>
          <population>The analysis was performed on an intention to treat basis. Individuals for whom ROP status could not be defined were treated as missing completely at random, and excluded from the analyses (50 Inositol and 35 Placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on the incidence of ROP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7464</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Robust Poisson regression</method>
            <method_desc>Model adjusted for strata defined by center and gestational age.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Type 2 or More Severe Retinopathy of Prematurity (ROP)</title>
        <description>Defined as one or both eyes reaching Type 2 ROP (ETROP 2003) or the more severe Type 1 ROP (as defined previously) through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)). Type 2 ROP is defined as (ETROP 2003): Stage 3 ROP without Plus Disease (i.e. Zone II) or Stage 1 or 2 ROP without Plus Disease (i.e. Zone I).</description>
        <time_frame>by 55 weeks PMA</time_frame>
        <population>The analysis was performed on an intention to treat basis. Individuals for whom ROP status and/or type could not be defined were treated as missing completely at random, and excluded from the analyses (54 Inositol and 36 Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Myo-Inositol 5% Injection</title>
            <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
          </group>
          <group group_id="O2">
            <title>5% Glucose(Dextrose)</title>
            <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Type 2 or More Severe Retinopathy of Prematurity (ROP)</title>
          <description>Defined as one or both eyes reaching Type 2 ROP (ETROP 2003) or the more severe Type 1 ROP (as defined previously) through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)). Type 2 ROP is defined as (ETROP 2003): Stage 3 ROP without Plus Disease (i.e. Zone II) or Stage 1 or 2 ROP without Plus Disease (i.e. Zone I).</description>
          <population>The analysis was performed on an intention to treat basis. Individuals for whom ROP status and/or type could not be defined were treated as missing completely at random, and excluded from the analyses (54 Inositol and 36 Placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on the incidence of Type 2 ROP or more severe ROP.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7598</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Robust Poisson regression</method>
            <method_desc>Model adjusted for strata defined by center and gestational age.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>In the risk ratio, the numerator represents the Inositol arm and the denominator represents the placebo arm. (RR&gt;1 implies that the risk of Type 2 ROP or more severe ROP is greater in the Inositol group compared to the Placebo group).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Intraventricular Hemorrhage (IVH)</title>
        <description>Severe IVH is defined as IVH Grades 3 or 4 on either side of the brain. The evaluation for IVH occurs early (within 28 days from birth) via a cranial sonogram and is classified as described by Papile.</description>
        <time_frame>by 28 days PMA</time_frame>
        <population>The analysis was performed on an intention to treat basis. Individuals for whom severe IVH status could not be defined were treated as missing completely at random, and excluded from the analyses (6 Inositol and 4 Placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Myo-Inositol 5% Injection</title>
            <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
          </group>
          <group group_id="O2">
            <title>5% Glucose(Dextrose)</title>
            <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Intraventricular Hemorrhage (IVH)</title>
          <description>Severe IVH is defined as IVH Grades 3 or 4 on either side of the brain. The evaluation for IVH occurs early (within 28 days from birth) via a cranial sonogram and is classified as described by Papile.</description>
          <population>The analysis was performed on an intention to treat basis. Individuals for whom severe IVH status could not be defined were treated as missing completely at random, and excluded from the analyses (6 Inositol and 4 Placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on the incidence severe IVH.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8133</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Robust Poisson regression</method>
            <method_desc>Model adjusted for strata defined by center and gestational age.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>In the risk ratio, the numerator represents the Inositol arm and the denominator represents the placebo arm. (RR&gt;1 implies that the risk of severe IVH is greater in the Inositol group compared to the Placebo group).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Occurrence of Adverse Events and Serious Adverse Events</title>
        <time_frame>7 days post study drug discontinuation</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Necrotizing Enterocolitis (NEC)</title>
        <description>Stage II or worse, whether treated (medically or surgically) and if the infant survived (modified Bell's classification [Walsh 1986]).</description>
        <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Isolated Gastrointestinal Perforation</title>
        <description>judged not to be due to NEC</description>
        <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Late Onset Sepsis</title>
        <description>culture positive septicemia/bacteremia (≥72 hours of age) treated with antibiotics for ≥ 5 days or died before treatment was completed.</description>
        <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patent Ductus Arteriosus (PDA)</title>
        <description>Occurrence of clinically significant patent ductus arteriosus (PDA), and if received intervention with prostaglandin inhibitors, and/or surgery.</description>
        <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seizures</title>
        <description>Seizures treated with an anticonvulsant for &gt;72 hours</description>
        <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Days on Parenteral Nutrition</title>
        <description>Total days on parenteral nutrition (including amino acids and/or lipids)</description>
        <time_frame>NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Days on Oxygen, Days on Ventilator</title>
        <time_frame>NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hearing Loss</title>
        <description>Hearing loss as defined as never passing a hearing screening in one or both ears</description>
        <time_frame>NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neurodevelopment</title>
        <description>Neurodevelopment at 22-26 months corrected age (i.e., 22-26 months past due date) using the Bayley Scales of Infant Development III.</description>
        <time_frame>22-26 months corrected age</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vision Loss</title>
        <description>Vision loss as diagnosed by an ophthalmologist as legally blind, and subdivided into &quot;ophthalmic origin&quot;, or &quot;not ophthalmic origin&quot; (i.e., cortical blindness is non-ophthalmic in origin and indicates that there is no retinal detachment or other abnormal fundus or ocular finding, except optic atrophy. Such cases will be considered central [neurologic] in origin.)</description>
        <time_frame>22-26 Months Corrected Age</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hearing Loss</title>
        <description>Hearing loss requiring that hearing aids be prescribed.</description>
        <time_frame>22-26 Months Corrected Age</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cerebral Palsy</title>
        <description>Cerebral palsy by severity category (absent/mild/moderate/severe).</description>
        <time_frame>22-26 Months Corrected Age</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Health Status</title>
        <description>Overall health status per recall from the parent/guardian (including survival, re-hospitalizations, surgeries, ongoing medications, and chronic illnesses).</description>
        <time_frame>22-26 Months Corrected Age</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be recorded from treatment initiation until 7 days after the last dose of study drug, up to the earliest of 34 weeks post-menstrual age (PMA), 10 weeks chronologic age (CA), or discharge.</time_frame>
      <desc>The at-risk population for all-cause mortality is the intent-to-treat (ITT) population which consists of all randomized participants (317 Inositol 321 Placebo). The at-risk population for serious adverse events and/or other (not including serious) adverse events is the safety-population which consists of all individuals who started treatment (313 Inositol 319 Placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>Myo-Inositol 5% Injection</title>
          <description>Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.</description>
        </group>
        <group group_id="E2">
          <title>5% Glucose(Dextrose)</title>
          <description>The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="313"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>CONGESTIVE HEART FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PDA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="313"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>POOR PERFUSION OR HYPOTENSION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="313"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PULMONARY VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>DELAYED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ELEVATED LIVER ENZYMES</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>EMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>NEC</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="313"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SPONTANEOUS INTESTINAL PERFORATION, WITHOUT NEC</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="313"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ESPHOGEAL PERFORATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>MECONIUM PLUG SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SYSTEMIC INFECTION</sub_title>
                <counts group_id="E1" events="55" subjects_affected="50" subjects_at_risk="313"/>
                <counts group_id="E2" events="39" subjects_affected="34" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="313"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERCALCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERNATREMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>IVH</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="313"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SEIZURES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DIURESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ELEVATED CREATININE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="313"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY AIR LEAK</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="313"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PULMONARY HEMORRHAGE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="313"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DETERIORATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="313"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPOXIC RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SUPERFICIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SKIN BREAKDOWN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SKIN CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="291" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="298" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="336" subjects_affected="185" subjects_at_risk="313"/>
                <counts group_id="E2" events="379" subjects_affected="202" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINEMIA</sub_title>
                <counts group_id="E1" events="69" subjects_affected="67" subjects_at_risk="313"/>
                <counts group_id="E2" events="63" subjects_affected="56" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="313"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="313"/>
                <counts group_id="E2" events="37" subjects_affected="26" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" events="108" subjects_affected="95" subjects_at_risk="313"/>
                <counts group_id="E2" events="119" subjects_affected="96" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>OTHER</sub_title>
                <description>Other (not including serious) adverse events under blood and lymphatic system disorders includes frank blood drainage from Penrose drain.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CONGESTIVE HEART FAILURE</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="313"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="313"/>
                <counts group_id="E2" events="36" subjects_affected="23" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PDA</sub_title>
                <counts group_id="E1" events="89" subjects_affected="88" subjects_at_risk="313"/>
                <counts group_id="E2" events="87" subjects_affected="87" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>POOR PERFUSION OR HYPOTENSION</sub_title>
                <counts group_id="E1" events="45" subjects_affected="36" subjects_at_risk="313"/>
                <counts group_id="E2" events="40" subjects_affected="30" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="313"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>OTHER</sub_title>
                <description>Other (not including serious) adverse events under cardiac disorders include atrial vegetation/thrombus, femoral continuous loop complication (under perfusion right leg and great toe)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLEOSTASIS</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="313"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>DELAYED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="76" subjects_affected="52" subjects_at_risk="313"/>
                <counts group_id="E2" events="95" subjects_affected="46" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ELEVATED LIVER ENZYMERS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="313"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>EMESIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>NEC</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SPONTANEOUS INTESTINAL PERFORATION WITHOUT NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENTION</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>BLOODY STOOL</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>BOWEL DYSFUNCTION</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ESOPHOGEAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>FEEDING INTOLERANCE</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>STRICTURES REQUIRING SURGERY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>GRANULATION TISSUE PROLAPSE (PENROSE DRAIN SITE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>LOCAL INFECTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="313"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SUPERFICIAL INFECTION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="313"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFECTION</sub_title>
                <counts group_id="E1" events="98" subjects_affected="76" subjects_at_risk="313"/>
                <counts group_id="E2" events="102" subjects_affected="84" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="97" subjects_affected="78" subjects_at_risk="313"/>
                <counts group_id="E2" events="88" subjects_affected="67" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ELEVATED 17-OH PROGESTERONE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>RICKETS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERNATREMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL MOVEMENTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>IVH</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="313"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SEIZURES</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="313"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>STATE OF ALERTNESS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DIURESIS</sub_title>
                <counts group_id="E1" events="83" subjects_affected="36" subjects_at_risk="313"/>
                <counts group_id="E2" events="77" subjects_affected="44" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ELEVATED CREATININE</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="54" subjects_affected="45" subjects_at_risk="313"/>
                <counts group_id="E2" events="58" subjects_affected="49" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>GLUCOSUIRA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="313"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" events="79" subjects_affected="46" subjects_at_risk="313"/>
                <counts group_id="E2" events="68" subjects_affected="46" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="313"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>RENAL DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>BILATERAL HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY AIR LEAK</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="313"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>PULMONARY HEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DETERIORATION</sub_title>
                <counts group_id="E1" events="172" subjects_affected="114" subjects_at_risk="313"/>
                <counts group_id="E2" events="171" subjects_affected="120" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>CHRONIC LUNG DISEASE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="313"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SKIN BREAKDOWN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>IV INFILTRATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ATOPIC DERMATITIS</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE NECROSIS (UPPER LIMB)</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>NASAL SEPTIC BREAKDOWN</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators must adhere to the Neonatal Research Network Publication policies.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to a manufacturing issue, enrollment and treatment were temporarily suspended pending review of primary outcome data for the enrolled infants. The statistically significant increase in mortality resulted in early study termination.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dale Phelps</name_or_title>
      <organization>University of Rochester</organization>
      <phone>(585) 275-2972</phone>
      <email>dale_phelps@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

